Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients

This is the first and only immunotherapy-based treatment approved for use before surgery for patients with non-small cell lung cancer

- PMLiVE

BMS and Century Therapeutics agree on deal potentially worth over $3bn

The collaboration unites Century’s iPSC-derived allogeneic cell therapy line with BMS’s record in developing oncology drugs and cell therapies

- PMLiVE

FDA approves first drug to prevent graft-versus-host disease

Bristol Myers Squibb’s arthritis drug, Orencia, can now be given to adults and children undergoing stem cell transplants to prevent the life-threatening condition

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

BMS reports strong growth as its Q3 results beat predictions

With revenues for the third quarter up by 10%, BMS hopes growth for Opdivo, Eliquis and new launches will offset inevitable generic competition for Revlimid

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

- PMLiVE

Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week

- PMLiVE

FDA to consider BMS’ Orencia for graft versus host disease

Leukaemia patients who receive stem cell transplant may gain access to Orencia by the end of the year

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

- PMLiVE

BMS’ Q2 results beat expectations with strong performance across core therapy areas

In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links